182 related articles for article (PubMed ID: 18442220)
1. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
Zhou Q; Yan XF; Pan WS; Zeng S
World J Gastroenterol; 2008 Apr; 14(16):2617-9. PubMed ID: 18442220
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in chirally pure proton pump inhibitors.
Pai V; Pai N
J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
5. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.
Lu M; Malladi V; Agha A; Abudayyeh S; Han C; Siepman N; Graham DY
Dig Dis Sci; 2007 Oct; 52(10):2813-20. PubMed ID: 17393309
[TBL] [Abstract][Full Text] [Related]
6. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
7. The pharmacology and clinical relevance of proton pump inhibitors.
Katz PO; Frissora C
Curr Gastroenterol Rep; 2002 Dec; 4(6):459-62. PubMed ID: 12441035
[TBL] [Abstract][Full Text] [Related]
8. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Thomson AB
Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
[TBL] [Abstract][Full Text] [Related]
9. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
10. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Maev IV; Balashova NN; Busarova GA
Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Kivioja A; Linnosmaa I; Vehviläinen A; Vohlonen I
Eur J Pharm Sci; 2004 Feb; 21(2-3):171-8. PubMed ID: 14757488
[TBL] [Abstract][Full Text] [Related]
12. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Pilotto A; Franceschi M; Leandro G; Scarcelli C; D'Ambrosio LP; Paris F; Annese V; Seripa D; Andriulli A; Di Mario F
World J Gastroenterol; 2007 Sep; 13(33):4467-72. PubMed ID: 17724802
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of proton pump inhibitors].
Herszényi L; Tulassay Z
Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
[TBL] [Abstract][Full Text] [Related]
15. An overview of proton pump inhibitors.
Der G
Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Pallotta S; Pace F; Marelli S
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):509-22. PubMed ID: 19072398
[TBL] [Abstract][Full Text] [Related]
17. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
18. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Hall J; Dodd S; Durkin M; Sloan S
Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
[TBL] [Abstract][Full Text] [Related]
19. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Robinson M
Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
